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Background: Obstructive lung diseases of different etiologies present with progressive 
peripheral airway involvement. The peripheral airways, known as the silent lung zone, are not 
adequately evaluated with conventional function tests. The principle of gas washout has been 
used to detect pulmonary ventilation inhomogeneity and to estimate the location of the underly-
ing disease process. Volumetric capnography (VC) analyzes the pattern of CO
2
 elimination as 
a function of expired volume.
Objective: To measure normalized phase 3 slopes with VC in patients with non-cystic fibrosis 
bronchiectasis (NCB) and in bronchitic patients with chronic obstructive pulmonary disease 
(COPD) in order to compare the slopes obtained for the groups.
Methods: NCB and severe COPD were enrolled sequentially from an outpatient clinic 
(Hospital of the State University of Campinas). A control group was established for the NCB group, 
paired by sex and age. All subjects performed spirometry, VC, and the 6-Minute Walk Test (6MWT). 
Two comparisons were made: NCB group versus its control group, and NCB group versus COPD 
group. The project was approved by the ethical committee of the institution. Statistical tests used were 
Wilcoxon or Student’s t-test; P,0.05 was considered to be a statistically significant difference.
Results: Concerning the NCB group (N=20) versus the control group (N=20), significant dif-
ferences were found in body mass index and in several functional variables (spirometric, VC, 
6MWT) with worse results observed in the NCB group. In the comparison between the COPD 
group (N=20) versus the NCB group, although patients with COPD had worse spirometric 
and 6MWT values, the capnographic variables mean phase 2 slope (Slp2), mean phase 3 slope 
normalized by the mean expiratory volume, or mean phase 3 slope normalized by the end-tidal 
CO
2
 concentration were similar.
Conclusion: These findings may indicate that the gas elimination curves are not sensitive 
enough to monitor the severity of structural abnormalities. The role of normalized phase 3 slope 
may be worth exploring as a more sensitive index of small airway disease, even though it may 
not be equally sensitive in discriminating the severity of the alterations.
Keywords: volumetric capnography, spirometry, bronchiectasis, 6MWT, bronchitis
Introduction
The physiological principles of gas washout were first described more than 60 years 
ago and two different tests have been developed from them for clinical use: the single 
breath and the multiple gas washout techniques. It is said that these tests allow the 
detection of pulmonary ventilation inhomogeneity and also permit an estimate of 
the location of the underlying disease process.1
Inert gases, such as helium (He), nitrogen (N
2
), and sulfur hexafluoride (SF
6
) have 
been used and the elimination curves that they produce during each expiration depict 
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concentrations of the gas at different volumes until all the 
expiratory volume is expired. Irrespective of the gas used, all 
of the curves are the same and in each of them three phases 
can be identified: phase 1, with very low concentrations of the 
gas, which corresponds to the elimination of the air that is in 
the anatomic dead space; phase 2, generally a steep upward 
line, that represents the growing concentration of the gas 
that is eliminated from proximal alveolated air spaces; and 
phase 3, that is almost a plateau line and represents the elimi-
nation of the gas from most of the alveoli in the lungs.
The peripheral airways have been termed the silent lung 
zone because the conventional lung function tests are unable 
to detect their involvement in disease processes.
The phase 3 slope is an important feature of gas washout 
curves and contains information about gas transport in the 
alveolated airways of the lung periphery. It varies in many 
pathological conditions of the lungs.2–7
Volumetric capnography is a technique that analyzes the 
pattern of CO
2
 elimination as a function of expired volume. 
It produces a curve, the capnogram, that represents the total 
amount of CO
2
 eliminated by the lungs during each breath. 
As we would expect, the capnogram has the same form as 
the other gas elimination curves, with the advantage of being 
obtained with a gas that is normally produced in the body 
and eliminated by the lungs.8,9
The objective of this study was to measure normalized 
phase 3 slopes with volumetric capnography in patients with 
non-cystic fibrosis bronchiectasis (NCB) and in patients with 
chronic obstructive pulmonary disease (COPD) with the 
bronchitic phenotype (cough, hypersecretion, wheezing) in 
order to compare the slopes obtained for the two groups.
Subjects and methods
Our hospital (teaching hospital of the State University of 
Campinas) is a reference center for pulmonary diseases and 
we select for outpatient follow-up all the non-smoker patients 
with chronic sputum production and the smoker patients 
with the most severe manifestations of COPD (among other 
diseases not related to this study).
Twenty patients with NCB (NCB group) and 20 patients 
with COPD (Global Initiative for Chronic Obstructive Lung 
Disease [GOLD] grade 3 and 4 of airflow limitation)10 with 
hypersecretion phenotype (chronic bronchitis [CB] group) 
were serially enrolled at the moment of their routine evaluation 
at our outpatient clinic. All patients who agreed to participate 
in the study were submitted to the pulmonary function tests 
(spirometry and volumetric capnography) and the 6-Minute 
Walk Test (6MWT) on the same day of their consultation.
A control group was established for the group of patients 
with bronchiectasis, paired by sex and age. These 20 subjects 
of the control group were volunteers who signed an informed 
consent form, and they all were nonsmokers, had no respira-
tory symptoms whatsoever, and no past or present history 
of lung disease. They all performed spirometry, volumetric 
capnography, and the 6MWT.
For the 6MWT, all patients were tested by the same tech-
nician under standardized conditions in accordance with the 
standards of the American Thoracic Society.11 Baseline blood 
pressure and heart rate were measured, and oxygen saturation 
(SpO
2
) was determined using a finger probe pulse oximeter 
(Nonin WristOx 3100™ (Nonin, Plymouth, MN, USA)). The 
pulse signal was carefully observed for at least 20 seconds, 
and the most frequent value on display, measured with a good 
pulse signal, was chosen. Saturation was measured at rest 
and immediately after the end of the 6-minute period, and 
the patients were carefully observed during the test to avoid 
dangerously exceeding their exercise limits. According to 
the American Thoracic Society guidelines,11 SpO
2
 should not 
be used for constant monitoring during the exercise and the 
technician must not walk with the patient to observe SpO
2
.
Desaturation was calculated as the resting oxygen satura-
tion minus oxygen saturation after the 6-minute period. For 
the purpose of data analysis, a cut-off value for desaturation 
of 4% was chosen, which means a decrease in SpO
2
 from 
baseline .4%. The 4% fall was validated in a study12 of 
exercise-induced hypoxemia during maximal exercise tests 
in athletes. Concerning the distance walked in the 6MWT, 
a cut-off of 400 m was chosen.
Pulmonary function tests were performed using a spiro meter 
(Easy one-PC®; ndd, Switzerland) and the values of forced vital 
capacity (FVC), forced expiratory volume in the first second 
(FEV
1
), and FEV
1
/FVC ratio were analyzed.  Reference values 
for the Brazilian population13 were used. FVC and FEV
1
 were 
expressed as a percent of the predicted value.
For the capnographic measurements, a CO
2
SMOS Plus 
8100 Dixtal/Novametrix® (Respironics, Murrisville, PA, 
USA) was used. The subjects remained breathing at tidal 
volume for a period of 4 minutes, during which time the vari-
ables were measured and the data were stored in the computer 
(software Analysis Plus®). At the end of data collection, an 
offline sequence of the respiratory cycles of the subjects was 
selected to accommodate a variation of ,15% for expiratory 
tidal volume and of ,5% for end-tidal concentration of CO
2
 
(EtCO
2
) tension. The respiratory cycles, those presenting 
phase 3 slope values of zero, were excluded; for each of the 
measurements a mean value was determined.
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The mean values of capnography, spirometry, and 
6MWT for the three groups (NCB, BC, and controls) were 
 determined. All subjects had their capnographic, spirometric, 
and variables of the 6MWT compared with the appropriate 
tests (Wilcoxon or Student’s t-test); differences were consid-
ered significant with P,0.05.
Approval for the use of patient data was obtained from 
the Research Ethics Committee of the Medical School of the 
State University of Campinas (UNICAMP).
Results
Clinical data (age, sex, body mass index [BMI]) and func-
tional data (spirometry, capnography, 6MWT) of subjects 
from the NCB group and the control group are shown in 
Table 1. All patients in the NCB group and the control group 
were nonsmokers. Concerning clinical parameters, only BMI 
Table 1 Comparison between patients with nCB and control 
group
NCB  
(N=20)
Control group  
(N=20)
P
age (years) 48.3±18.4 47.1±16.6 0.823**
BMI (Kg/m2) 23.1±4.7 25.4±2.7 0.022*
FeV1 (% predicted) 56.5±18.4 99.3±19.6 ,0.0001**
FVC (% predicted) 64.6±13.1 97.5±18.7 ,0.0001**
FeV1/FVC 70.4±14.6 81.9±14.6 0.011*
PeF (% predicted) 51.3±14.6 58.7±36.6 0.245*
6MWD (m) 445.7±159.9 538.9±90.8 0.006*
Δ saturation (%) −0.4±1.6 0.9±1.1 0.001**
Ve (ml) 502.0±150.0 589.5±150.0 0.120**
Te (s) 2.3±0.5 2.8±0.5 0.060*
Ti (s) 1.5±0.4 1.8±0.4 0.027**
slope 2 (mmhg/l) 257.7±109.3 332.0±100.6 0.031**
slope 3/Ve 0.07±0.06 0.02±0.06 ,0.001*
slope 3/etCO2 0.9±0.4 0.3±0.1 ,0.0001*
MV (l) 8.0±2.1 7.6±2.1 0.607**
rr (cicles/m) 16.5±3.4 13.8±4.1 0.033**
Ve (ml/Kg) 8.6±2.7 8.4±2.3 0.798**
Vd/Vt aw 0.30±0.08 0.26±0.06 0.072**
etCO2 32.9±5.2 35.1±4.3 0.157**
VCO2/br 10.2±3.5 15.5±6.8 0.008*
VCO2 (ml/m) 157.5±8.3 192.6±10.6 0.013**
Notes: all spirometric measurements (FVC, FeV1, and PeF) correspond to the 
values obtained after the use of bronchodilator. *Mann–Whitney test; **student’s 
t-test; values expressed in mean ± sD; P,0.05 was considered to be a statistically 
significant difference.
Abbreviations: 6MWD, walked distance in the 6-minute walk test; Δ saturation, 
difference between baseline pulse saturation and saturation at the final of the 
6-minute walk test; BMI, body mass index; etCO2, end-tidal CO2; FeV1, forced 
expiratory volume in 1 second; FVC, forced vital capacity; MV, quantity of air inhaled 
expressed in terms of volume per minute; NCB, non-cystic fibrosis bronchiectasis; 
PEF, peak of expiratory flow; RR, respiratory rate; SD, standard deviation; Slope 3/
etCO2, slope 3 normalized by end-tidal CO2; slope 3/VT, slope 3 normalized by 
tidal volume; Te, duration of the expiratory phase; Ti, duration of the inspiratory 
phase; VCO2, the volume of CO2 produced; VCO2/br, excretion of CO2 per breath; 
Vd/Vt aw, deadspace volume by tidal volume ratio; Ve, expired tidal volume.
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Figure 1 Comparison between mean values of spirometric parameters of the three 
groups: control, nCB, and COPD (FeV1 and FVC shown as percentage predicted 
value).
Notes: *P,0.0001; **P=0.01; †P.0.05.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced 
expiratory volume in the first second; FVC, forced vital capacity; NCB, non-cystic 
fibrosis bronchiectasis.
was different between the two groups, with higher values in 
the control group (P=0.022).
As for spirometric variables, determined after the use of 
bronchodilator, FEV
1
 (P,0.0001), FVC (P,0.0001) and 
FEV
1
/FVC ratio (P=0.011) were worse in NCB patients. 
The NCB group had FVC less than the lower limit of the 
range of predicted values more often than the control group 
(P,0.0001) (Figure 1).
The mean 6MWT distance was lower in the bronchiectasis 
group compared with control group (P=0.006) and no signifi-
cant drop in saturation happened at the end of the 6-minute 
walk in either group.
Regarding capnographic variables, mean expiratory tidal 
volume (Ve), mean expiratory volume normalized by weight 
in kilograms (Ve/kg), mean expiratory time (Te), mean min-
ute volume (MV), mean airway dead space (VD/VT aw), 
mean peak expiratory flow (PEF), and mean EtCO
2
 were 
similar in the NCB and control groups. The mean inspira-
tory time was longer in the control group (P=0.028); the 
mean total respiratory rate (RR) was higher in patients with 
bronchiectasis. The mean Slp2 was lower in NCB patients 
(P=0.031); the mean phase 3 slope normalized by the mean 
expiratory volume (Slp3/Ve) or by the EtCO
2
 concentration 
(Slp3/EtCO
2
) was greater in NCB patients (P=0.0003 and 
P,0.0001, respectively). The mean volume of CO
2
 elimi-
nated during each breath was higher in the control group.
The comparison between the group of patients with 
bronchiectasis and the group of patients with severe COPD 
(GOLD 3 and 4) showed that bronchitic COPD patients were 
significantly older (P,0.001), but the two groups had similar 
BMIs. The data of the groups are shown in Table 2.
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As for spirometric variables, patients with bronchiecta-
sis (NCB group) had significantly better FEV
1
, FEV
1
/FVC, 
and PEF than the patients with chronic bronchitis COPD 
(COPD group) (P,0.001, P,0.0001, and P=0.002, respec-
tively). Both groups had measurements of FVC below the 
lower limit of the expected value with high and similar 
frequency (90% for the NBC group, 95% for the COPD 
group) (Figure 1).
Eighty percent of bronchiectasis patients had an FEV
1
/
FVC ratio greater than 0.7 and 95% of the patients with 
chronic bronchitis had it lower than 0.7 (P,0.0001).
In the 6MWT, mean walk distance was lower in patients 
with chronic bronchitis (P=0.044), as well as the saturation 
before the test (P,0.001). A fall of four or more percentage 
points at the end of the 6MWT was more frequent among 
patients with chronic bronchitis than among the subjects 
with bronchiectasis (P=0.029), as was the finding of a walk 
distance shorter than 400 m (P=0.027).
Regarding capnographic variables, Ve, Te, Ti, MV, RR, 
Ve/kg, V
D
/V
T
 aw, and PEF were similar in COPD and NCB 
groups. Also no significantly different values for Slp2, 
Slp3/Ve, and Slp3/EtCO
2
 were found. The EtCO
2
, VCO
2
/
br, and VCO
2
 were significantly higher in COPD than in 
NCB patients (P=0.024, P=0.041, P=0.006, respectively) 
(Figure 2).
Discussion
The analysis of the results of the comparison between the 
group of NCB patients and the control group, regarding the 
spirometric variables, shows that patients were significantly 
different from controls and had moderate obstructive disease 
with reduced FVC.
In the 6MWT, the NCB patients walked shorter distances 
than the controls, but the mean distance walked was greater 
than 400 m, a figure accepted as within normal limits.
In the capnographic measurements, the values of Slp2 
(smaller), and of Slp3/Ve and Slp3/EtCO
2
 (greater), for the 
NCB group were significantly different from the control group. 
The Slp2 depicts the removal of CO
2
 from the alveoli, which 
are at the end of smaller airway paths. The branching of the 
bronchial tree, designed to fill the volume of the chest, allows 
the existence of paths of different lengths to the membrane for 
gas exchange; ie, to the alveoli. The more or less rapid rise 
in the concentration of CO
2
 in exhaled air at the end of the 
elimination of air from the anatomic dead space determines 
the slope of phase 2 of the volumetric capnogram and reflects 
the elimination of CO
2
 that comes from these shortest paths. 
Steeper slopes of phase 2 allow us to suppose that there are 
short branches of the bronchial tree occupying all spaces 
located within short distances from the central axis of the 
tree (the trachea). Therefore, normal individuals should have 
greater Slp2 than patients with lung diseases that reduce the 
number of these short paths. Phase 3 of the volumetric capno-
gram represents the elimination of CO
2
 from most of the alveoli 
and in normal individuals is almost a plateau, with a slight 
upward slope. The Slp3 should therefore be small. Increases 
in Slp3 happen in situations of heterogeneous involvement of 
the distal air spaces, which lead to heterogeneous distribution 
of the air in these regions and reduced area of contact between 
the CO
2
 that crosses the alveolar–capillary membrane and the 
renewed air that arrived in the previous inspiration. Larger val-
ues of Slp3/Ve and Slp3/EtCO
2
 in patients suggest the existence 
of structural damage to the peripheral lung, which promotes 
this heterogeneous distribution of ventilation.2,3
The comparison between the NCB group and the group of 
patients with COPD GOLD 3 and 4 revealed that individu-
als with COPD had much worse spirometric values, walked 
less than 400 m, and desaturated four or more percentage 
points with a significantly higher frequency than patients 
with bronchiectasis (Table 2).
Spirometry and the 6MWT were able to demonstrate that 
individuals with COPD had worse disease than patients with 
bronchiectasis. However, the capnographic variables Slp2, 
Slp3/Ve, and Slp3/EtCO
2
 were similar in both groups.
Table 2 Comparison between patients with nCB and COPD 
patients
Variable NCB  
(N=20)
COPD  
(N=20)
P-value
age (years) 48.3±18.4 65.7±7.4 ,0.001*
BMI (Kg/m2) 23.1±4.7 25.0±6.2 0.278**
FVC (% predicted) 64.6±13.1 56.8±12.2 0.059**
FeV1 (% predicted) 56.5±18.4 36.9±12.3 ,0.001**
FeV1/FVC 70.4±14.6 50.4±10.3 ,0.0001**
PeF (% predicted) 51.3±19.8 32.6±14.1 0.002**
spO2 (%) 96.1±2.6 92.3±1.8 ,0.0001**
6MWD (m) 445.7±159.9 353.8±88.2 0.044*
Δ saturation (%) −0.4±1.6 −2.4±1.9 ,0.001*
slope 2 (mmhg/l) 257.7±109.3 235.5±93.2 0.493**
slope 3/Ve 0.08±0.06 0.07±0.05 0.749**
slope 3/etCO2 0.93±0.46 0.94±0.33 0.992**
Notes: all spirometric measurements (FVC, FeV1, and PeF) correspond to the 
values obtained after the use of bronchodilator. *Mann–Whitney test; **student’s 
t-test; values expressed in mean ± sD; P,0.05 was considered to be a statistically 
significant difference.
Abbreviations: 6MWD, walked distance in the 6-minute walk test; Δ saturation, 
difference between baseline pulse saturation and saturation at the final of the 
6-minute walk test; BMI, body mass index; COPD, chronic obstructive pulmonary 
disease; etCO2, end-tidal CO2; FeV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; NCB, non-cystic fibrosis bronchiectasis; PEF, peak 
of expiratory flow (L/second); SD, standard deviation; Slope 3/EtCO2, slope 3 
normalized by etCO2; slope 3/Ve, slope 3 normalized by expired tidal volume; 
spO2, oxygen saturation.
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These findings may show that capnography is not able to 
differentiate between the different types of structural disease 
shown by these groups, and is not sensitive to the worse 
clinical condition of the COPD patients.
It is very difficult to monitor the progression of structural 
abnormalities in both diseases (NCB and COPD) and this 
was not a longitudinal study, so making statements about 
progression is not appropriate.
Cosio et al,14 in a fundamental study published in 1978, 
demonstrated that structural changes in small airways of sus-
ceptible smokers with smoking histories greater than 35 pack-
years could be reflected in the nitrogen single-breath washout 
test. Increasing pathology scores (that included evaluation of 
inflammatory cell infiltrate, squamous cell metaplasia of the 
airway epithelium, and airway wall fibrosis) of the small airways 
(,2 mm internal diameter) were accompanied by increasing 
ventilation heterogeneity as measured from the N
2
 phase 3 slope 
of the single-breath washout test. This test of unevenness of 
ventilation could detect structural changes in the small airways 
of smokers long before spirometry could. But this measurement 
produced deceiving results in predicting decline of FEV
1
15,16 
and these data agree with the findings in this study.
The pattern of decreasing or increasing gas concentrations 
during the multiple-breath washout tests has the potential 
to anatomically locate the affected small airways in acinar 
and conductive lung zones through increased phase 3 slope 
indices S
acin
 (acinar lung zone) and S
cond
 (conductive lung 
zone).17 These calculations allowed the determination of the 
relative contribution of conductive and acinar airspaces in 
diseases such as asthma,18 cystic fibrosis,19 and COPD,20 and 
in conditions such as aging.21
In volumetric capnography, CO
2
 concentration is analyzed 
during multiple breaths, on average more than 50 breaths, 
but the pattern of elimination for an individual shows small 
variations from breath to breath due to the steady supply of 
CO
2
 to the lungs. This aspect of volumetric capnography 
probably makes it less informative than the classical, sophis-
ticated, and more expensive multiple-breath washout tests.
Nevertheless, perhaps the natural histories of both diseases 
evaluated here have differences that justify the findings of the 
present study. Chronic bronchitis associated with smoking is 
caused by the toxic action of many substances produced by 
burning tobacco that are repeatedly inhaled by the smokers. 
Generally all smokers have a productive cough, at least in the 
morning soon after waking up; however, not all smokers will 
have airflow obstruction on spirometry. Those individuals who 
develop obstructive disease are characterized as COPD patients. 
The airflow obstruction in COPD happens when there are struc-
tural changes in small airways and/or alveoli.22,23 Apparently, 
all smokers have proximal airway injury, but only a variable 
percentage also have peripheral structural lesions.10
Patients with severe COPD thus have proximal and 
distal changes in the airways that are sequential or almost 
simultaneous, but may certainly occur earlier in the proxi-
mal airways. The reason why only a few smokers develop 
COPD is still unknown. However, it can be speculated that 
the structure of the bronchial tree may be one of many fac-
tors that favor the onset of the disease. Simplification of the 
bronchial tree branching, either congenital or acquired in 
the postnatal period as a result of an infection in childhood, 
may facilitate the action of toxic substances from cigarettes, 
allowing them to reach further down the airways.
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Figure 2 Curves of volumetric capnography of control (A), bronchiectasis (B), and COPD (C) groups (representative curves).
Notes: (A) etCO2 =35.1 mmhg; Ve =590 ml; slope 3=11.17 mmhg/l. (B): etCO2 =32.9 mmhg; Ve =502 ml; slope 3=32.05 mmhg/l. (C) etCO2 =36.8 mmhg; Ve =589 ml; 
slope 3=34.10 mmhg/l.
Abbreviations: COPD, chronic obstructive pulmonary disease; etCO2, end-tidal CO2.
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Bronchiectasis appears to have a different natural history. 
The initial lesion in bronchiectasis most likely occurs in the 
small airways (bronchioles of less than 2 mm in diameter). 
Evidence supporting this hypothesis is available for cystic 
fibrosis, a disease that progresses with extensive dilation of 
central bronchi. Before bronchiectasis appears, clear signs of 
small airways disease are detectable by lung function evalu-
ation and imaging studies such as a computed tomography 
(CT) scan of the chest.24 In cystic fibrosis, the mucociliary 
transport is severely compromised by the reduced amount 
of water in the periciliary liquid.25–27
In ciliary dyskinesia, a disease that also causes dilation of 
the central bronchi, CT signs of bronchiolitis, especially the 
pattern described as “tree-in-bud” on high-resolution CT scans 
of the chest, are very often found in areas of the lung without 
dilated central bronchi. The loss of cilia beating in subjects 
with ciliary dyskinesia decreases the efficiency of mucociliary 
transport, a situation that seems to be common to many of the 
diseases that cause bronchiolitis/bronchiectasis.26
Again, the structure explains the importance of lung 
mucociliary transport for the removal of secretions in the 
small airways. Bronchial branching does significantly 
increase the cross-sectional area of the distal airspaces. The 
movement of gases by pressure (convection), which gener-
ates airflow, happens to some extent in the airways. The 
increased cross-sectional area in the distal air spaces causes 
airflow to drop dramatically. Failure to maintain adequate 
flow interferes with the ability to generate effective cough. 
Without cough, elimination of respiratory secretions, that 
trap biological and non-biological particles and many diluted 
or cross-linked toxic substances, is entirely dependent on 
mucociliary transport.28
In idiopathic bronchiectasis, although the causative 
mechanism of mucociliary transport impairment is 
unknown, the presence of tomographic signs of bronchiolitis 
in lung regions where dilatation of the central bronchi are 
not yet detected has been demonstrated; other areas show 
both bronchiolitis and bronchiectasis.29
In 1950, Reid30 published a cornerstone study on the 
pathology of extensive bronchiectasis, whose conclusions 
cleared many intriguing aspects of this condition. One of 
the most important findings was the reduction of bronchial 
subdivisions between the hilum and the periphery of the 
lung, especially in the saccular type of bronchiectasis. The 
missing bronchi, whenever their remnants could be identified, 
were obliterated by fibrous tissue and all the generations of 
bronchi and small airways that should arise from them had 
completely disappeared.
The combination of these findings with the visualization 
of signs of small airway disease on high-resolution CT scans 
of the chest (air trapping and/or tree-in-bud) allow us to 
hypothesize that in diffuse bronchiectasis the most important 
and probably most initial lesions occur in the small airways 
of less than 2 mm in diameter because their dependence on 
mucociliary clearance and other airway defense mechanisms 
is much greater than in central airways. The accelerated and 
heterogeneous loss of small airways, through inflammation 
and fibrous obliteration, may lead to a highly variable distri-
bution of gases in the distal air spaces and a reduction in the 
area of contact between the gas in the alveoli and the new 
gas that arrives at each inspiration.
These lesions may happen earlier and be more intense in 
conditions that cause diffuse bronchiectasis than in COPD 
patients and the slope of phase 3 in the volumetric capnogram 
and other single-breath washout curves could be specially 
suited to detect them.
Dutrieue et al,31 in their work published in 2000, demon-
strated that the phase 3 slope, which is generally referred to 
as a marker of small airway alterations, showed great sen-
sitivity to intra-acinar asymmetry, which can be a property 
of the acinus related to the asymmetric branching pattern of 
the airways or may be produced or aggravated by disease 
conditions that affect distal airspaces.
The lung clearance index (LCI), derived from the con-
centration curves obtained during a multiple-breath washout 
and used to quantify the inefficiency in gas mixing in the 
lungs, has been considered a valuable tool for early detec-
tion of lung structure alterations in children with cystic 
fibrosis.1,32,33
But Verbanck et al,34 in their work published in 2012, 
concluded that although LCI can potentially be affected by 
a structural change in the small airways, it can be modified 
likewise by structural changes in more proximal airways. 
In addition, a simple increase in anatomical dead space 
(common in bronchiectasis patients) leads to an LCI increase. 
Hence, LCI is not a small airway test in the sense that any 
observed change in LCI cannot be readily interpreted as the 
unequivocal reflection of a structural alteration of the small 
airways.
The role of normalized phase 3 slope may be worth 
exploring as a more sensitive index of small airway 
disease, even though it may not be equally sensitive in 
discriminating the severity of the alterations. Volumetric 
capnography may be an easier and less expensive way 
of measuring phase 3 slopes in a significant number of 
chronic lung diseases.
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